Jeeva Informatics Solutions
SaaS Platform Decentralizing Clinical Research at Scale
Global clinical trials activity decreased by 2.9% in Q2 2020, when compared with the same quarter in 2019, according to GlobalData.
Industry-sponsored trials accounted for a 46.1% share of overall activity in Q2 2020, an increase of 1.3% when compared with Q2 2019.
Non-industry-sponsored trials accounted for a 53.9% share of all clinical trials in Q2 2020, marking a decrease of 1.3% when compared with the same period in 2019.
Q2 2020 industry-sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry-sponsored clinical trials in Q2 2020, accounting for a 28.3% share of all trials.
This was followed by infectious disease with a 25.8% share, central nervous system with 10.8%, respiratory with 9.6% and metabolic disorders with 6.6%.
In Q2 2019, oncology led with a 27.9% share, followed by central nervous system with 14.4%, infectious disease with 10.1%, metabolic disorders with 9.4%, and cardiovascular with 8.6%.
Industry-sponsored trials: Q2 2020 vs Q2 2019 | |||
---|---|---|---|
Therapy Area | Q2 2019 | Q2 2020 | Activity |
Oncology | 27.9% | 28.3% | ![]() |
Infectious Disease | 10.1% | 25.8% | ![]() |
Central Nervous System | 14.4% | 10.8% | ![]() |
Respiratory | 5.5% | 9.6% | ![]() |
Metabolic Disorders | 9.4% | 6.6% | ![]() |
Cardiovascular | 8.6% | 6.0% | ![]() |
Gastrointestinal | 7.0% | 5.5% | ![]() |
Immunology | 5.9% | 4.9% | ![]() |
Dermatology | 4.9% | 4.1% | ![]() |
Genito Urinary System And Sex Hormones | 2.7% | 2.7% | ![]() |
Musculoskeletal Disorders | 5.3% | 2.7% | ![]() |
Hematological Disorders | 3.6% | 2.6% | ![]() |
Ophthalmology | 3.0% | 2.5% | ![]() |
Women’s Health | 2.4% | 1.7% | ![]() |
Genetic Disorders | 1.7% | 1.6% | ![]() |
Male Health | 0.6% | 1.0% | ![]() |
Ear Nose Throat Disorders | 1.1% | 0.9% | ![]() |
Hormonal Disorders | 0.8% | 0.4% | ![]() |
Mouth and Dental Disorders | 0.7% | 0.4% | ![]() |
Non Malignant Disorders | 0.3% | 0.2% | ![]() |
Nutritional Disorders | 0.7% | 0.2% | ![]() |
Most active therapy areas in non-industry-sponsored clinical trials
GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.
Find out moreIn Q2 2020 the leading therapy area for non-industry-sponsored clinical trials was infectious disease, accounting for a 34.9% share of all trials.
This was followed by oncology with a 20.0% share, central nervous system with 16.3%, respiratory with 10.1%, and cardiovascular with 7.0%.
In Q2 2019, central nervous system held the lead in non-industry-sponsored clinical trials with a 26.0% share, followed by oncology with 19.8%, cardiovascular with 9.6%, metabolic disorders with 7.8%, and gastrointestinal with 7.7%.
Non-Industry-sponsored trials: Q2 2020 vs Q2 2019 | |||
---|---|---|---|
Therapy Area | Q2 2019 | Q2 2020 | Activity |
Infectious Disease | 7.3% | 34.9% | ![]() |
Oncology | 19.8% | 20.0% | ![]() |
Central Nervous System | 26.0% | 16.3% | ![]() |
Respiratory | 3.9% | 10.1% | ![]() |
Cardiovascular | 9.6% | 7.0% | ![]() |
Gastrointestinal | 7.7% | 5.4% | ![]() |
Metabolic Disorders | 7.8% | 4.1% | ![]() |
Women’s Health | 6.3% | 4.0% | ![]() |
Musculoskeletal Disorders | 5.7% | 3.6% | ![]() |
Immunology | 2.9% | 2.9% | ![]() |
Hematological Disorders | 3.3% | 2.7% | ![]() |
Genito Urinary System And Sex Hormones | 3.6% | 2.2% | ![]() |
Dermatology | 3.2% | 2.1% | ![]() |
Mouth and Dental Disorders | 2.6% | 1.4% | ![]() |
Ear Nose Throat Disorders | 1.4% | 1.1% | ![]() |
Ophthalmology | 2.0% | 1.1% | ![]() |
Genetic Disorders | 0.7% | 0.7% | ![]() |
Nutritional Disorders | 0.7% | 0.5% | ![]() |
Male Health | 1.0% | 0.4% | ![]() |
Hormonal Disorders | 1.2% | 0.3% | ![]() |
Non Malignant Disorders | 0.5% | 0.3% | ![]() |
Asia-Pacific region has the most activity for industry-sponsored clinical trials
Asia-Pacific was the most active region for industry-sponsored clinical trials activity in Q2 2020 with a 47.9% share, compared with 52.0% in Q2 2019.
North America was the second most active region with a 34.7% share in Q2 2020, up from 33.3% in Q2 2019, followed by Europe with a 28.0% share in Q2 2020, down from 29.2% in Q2 2019.
Single country studies held an 85.4% share in industry-sponsored clinical trials in Q2 2020, compared with 84.1% in Q2 2019. Multinational trials accounted for 14.6% in Q2 2020, against 15.9% in Q2 2019.
Regional activity for non-industry-sponsored clinical trials
Asia-Pacific saw the most non-industry-sponsored clinical trial activity in Q2 2020 with a 41.0% share, down from 54.4% in Q2 2019.
Middle East and Africa held the second position with a 19.9% share in Q2 2020, compared with 16.1% in Q2 2019. This was followed by North America with a 19.9% share in Q2 2020, as against 16.4% in Q2 2019.
Single country studies accounted for 98.8% share of non-industry-sponsored clinical trials in Q2 2020, compared with 98.9% in Q2 2019. Multinational trials accounted for a 1.2% share in Q2 2020, up from 1.1% in Q2 2019.
Clinical trials by phase in Q2 2020
Phase II trials outnumbered all other studies with a 39.5% share for industry-sponsored trials in Q2 2020, compared with 33.8% in Q2 2019.
The share of Phase I trials stood at 30.0% in Q2 2020, down from 37.2% in Q2 2019. Phase III trials increased to 20.0% in Q2 2020, compared with 17.2% in Q2 2019, followed by Phase IV trials with a 10.5% share in Q2 2020, against 11.8% in Q2 2019.
For non-industry-sponsored clinical trials, Phase II activity decreased to a 43.7% share in Q2 2020, compared with 47.7% in Q2 2019.
Phase III trials were the second most active with a 23.8% share in Q2 2020, compared with 18.7% in Q2 2019. Phase IV trials held an 18.1% share in Q2 2020, against 19.5% in Q2 2019, followed by Phase I trials with a 14.5% share in Q2 2020, over 14.1% in Q2 2019.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
SaaS Platform Decentralizing Clinical Research at Scale
Nanofibre and Nanoparticle Production Systems
Software Solutions for Clinical Trial and Medical Research Project Management